A Phase 3 interventional study of LY900003 in Carcinoma, Non-Small-Cell Lung, sponsored by Eli Lilly and Company. Completed at 105 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-07-19.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The purposes of this study are to determine:
It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate LY900003 plus gemcitabine and cisplatin for other possible uses or for other medical or scientific purposes other than those currently proposed.
LY900003 may not add any benefit to gemcitabine plus cisplatin.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
Browse Lung Neoplasms studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Showing the first 100 of 105 sites across 21 countries.
This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company